Select Bibliography

Filter by any of these (after searching):

Knopp, Michael V

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 8 items

Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET) After Progression on Prior Therapy (CABINET Trial): Updated Progression Free-Survival (PFS) Results by Blinded Independent Central Review (BICR) (Alliance)

Chan, Jennifer A , Geyer, Susan , Zemla, Tyler , Knopp, Michael V ... - ESMO - Annals of Oncology - 2024

Abstract - Primary - Primary - GI - Alliance-A021602

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.

Chan, Jennifer A , Geyer, Susan , Zemla, Tyler , Knopp, Michael V ... - - N Engl J Med - 2025

Manuscript - Primary - Primary - GI - Alliance-A021602

Updated Results of CABINET Trial/Alliance A021602: Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET) after Progression on Prior Therapy

Halfdanarson, Thorvardur R , Geyer, Susan , Zemla, Tyler ... - NANETS - - 2024

Abstract - Primary - Primary - GI - Alliance-A021602

Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC

Hensing, Thomas A. , Wang, Xiaofei , Stinchcombe, Thomas E. ... - - JTO Clin Res Rep - 2021

Manuscript - Primary - Primary - Respiratory - AFT-09

Local Review versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial (Alliance)

Ruppert, Amy S. , Pederson, Levi D. , Knopp, Michael V. , Poon, David ... - ASH - Blood - 2020

Abstract - Secondary-not-in-original - Primary - Lymphoma - CALGB-50303

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

Schöder, Heiko , Polley, Mei-Yin C. , Knopp, Michael V. ... - - Blood - 2020

Manuscript - Secondary - Primary - Lymphoma - CALGB-50303 , CALGB-580603

Radiation treatment volumes before and after BRAF/MEK therapy in newly diagnosed papillary craniopharyngiomas: A correlative analysis of the Alliance A071601 phase II trial

Shih, Helen A. , Tabrizi, Shervin , Kabat, Brian F. , Twohy, Erin ... - SNO - Neuro-oncology - 2021

Abstract - Secondary - Primary - Neuro-Onc - Alliance-A071601

Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis

Torka, Pallawi , Pederson, Levi D. , Knopp, Michael V. , Poon, David ... - - Cancer Med - 2023

Manuscript - Secondary-not-in-original - Primary - Lymphoma - CALGB-50303 , CALGB-580603